IRWD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IRWD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Ironwood Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $202.7 Mil.
Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Ironwood Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $512.9 Mil.
The historical data trend for Ironwood Pharmaceuticals's Short-Term Debt & Capital Lease Obligation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ironwood Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Short-Term Debt & Capital Lease Obligation | Get a 7-Day Free Trial | 1.15 | 3.13 | 119.99 | 3.07 | 202.69 |
Ironwood Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Short-Term Debt & Capital Lease Obligation | Get a 7-Day Free Trial | 3.07 | 3.08 | 202.18 | 202.43 | 202.69 |
This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.
In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.
Be Aware
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.
Marla L Kessler | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Andrew Davis | officer: SVP, Chief Business Officer | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Sravan Kumar Emany | officer: SVP, Chief Financial Officer | 100 SUMMER ST, SUITE 2300, BOSTON MA 02109 |
Ronald Silver | officer: Principal Accounting Officer | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Minardo John | officer: Chief Legal Officer | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Thomas A Mccourt | officer: Chief Commercial Officer | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Michael Shetzline | officer: CMO,SVP,Head-Res&Drug | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Jason Rickard | officer: SVP, Chief Operating Officer | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Mark G Currie | officer: Chief Scientific Officer | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Julie Mchugh | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Sarissa Capital Management Lp | 10 percent owner | 660 STEAMBOAT ROAD, GREENWICH CT 06830 |
Alexander J Denner | director | C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Edward P Owens | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Gina Consylman | officer: Chief Accounting Officer | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Kilroy Conor | officer: SVP, GC & Secretary | 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
From GuruFocus
By GuruFocus Research • 10-17-2023
By Business Wire • 06-29-2023
By GuruFocus Research • 10-05-2023
By Business Wire Business Wire • 05-08-2023
By GuruFocus Research • 12-14-2023
By GuruFocus Research • 09-27-2023
By Business Wire Business Wire • 05-22-2023
By Business Wire • 10-26-2023
By Business Wire Business Wire • 06-16-2023
By Business Wire • 11-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.